KENNETH R HESS to Adenocarcinoma
This is a "connection" page, showing publications KENNETH R HESS has written about Adenocarcinoma.
Connection Strength
0.563
-
New option for the initial management of metastatic pancreatic cancer? J Clin Oncol. 2014 Aug 10; 32(23):2405-7.
Score: 0.133
-
Metastatic patterns in adenocarcinoma. Cancer. 2006 Apr 01; 106(7):1624-33.
Score: 0.075
-
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 2000 Nov; 232(5):727.
Score: 0.052
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.039
-
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011; 16(1):61-70.
Score: 0.026
-
Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
Score: 0.025
-
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9.
Score: 0.023
-
Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 2005 Jun 15; 103(12):2485-90.
Score: 0.018
-
Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
Score: 0.018
-
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):440-9.
Score: 0.017
-
Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004 Jul 01; 101(1):58-65.
Score: 0.017
-
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7.
Score: 0.017
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002 Sep 15; 20(18):3792-803.
Score: 0.015
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002 Sep 15; 20(18):3804-14.
Score: 0.015
-
Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
Score: 0.015
-
Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12.
Score: 0.014
-
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77.
Score: 0.012
-
Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87.
Score: 0.010
-
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66.
Score: 0.010
-
Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994 Jan; 1(1):73-8.
Score: 0.008
-
Unknown primary tumors metastatic to liver. J Clin Oncol. 1998 Jun; 16(6):2105-12.
Score: 0.003
-
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
Score: 0.002
-
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80.
Score: 0.002